Neo-Feudal Living Through Mainstream Media Propaganda Financed By Big Pharma

Everything is fake these days, especially financial news, which spills over boundlessly into politics and society. The fact that Big Pharma is the main funding source for mainstream media brings into question everything about the COVID-19 pandemic and government and media response.

In case there's any doubt, consider the recent news reporting on a Veteran's Affairs hospital study which concluded that Hydroxychloroquine - a generic drug used to treat malaria - is not a reliable treatment for coronavirus. Being mindful that the treatment, combined with Azithromycin in some cases, and in conjunction with zinc in early stage COVID-19 sufferers, has proven effective in shortening the length of time from infection to recovery, it's difficult to buy the claims by the study's authors, though that's exactly what the anti-Trump, big pharma-owned mainstream media did.

Never mind that President Trump was a big fan of Hydroxychloroquine, or that the research was neither done with random sampling nor was peer reviewed. The media just took the bait and ran with it, ostensibly in favor of the Gilead Science's more expensive proprietary drug, remdesivir, which is about to undergo real clinical trials.

Bear in mind that the mainstream media, especially television news, is sponsored mainly by Big Pharma. In between the two-to-four minute bouts of propaganda, commercials for drugs to treat everything from cancer to strokes to foot fungus are paid for by the likes of Pfizer, Roche, Novartis, Johnson and Johnson, Merck, Sanofi, AbbVie, Glacxo Smith Kline (GSK), Amgen, Gilead Sciences, and others. Here's a list of the Top 50 global pharma companies, which are also among the leading political donors.

The use of Hydroxychloroquine in conjunction with zinc and azithromycin for treatment of COVID-19 patients has been the focus of French physician and microbiologist, Dr. Didier Raoult,

Rauolt's twitter feed - mostly in French - is very active and strongly in favor of the treatment, which he claims limits the severity of the disease and shortens recovery time.

In the United States and in many developed countries, the mainstream media outlets, plus Google and Facebook, have been actively censoring Dr. Raoult's findings, the most recent of which involved successful treatment of 3000 patients, resulting in a death rate of 0.5 percent.

Raoult has extensive experience in treating viruses and getting positive results and is highly respected within the scientific community. His work spans decades and is frequently cited in leading medical journals. So, why does the mainstream media downplay or censor the importance of his work? Because hydroxychloroquine is very inexpensive (about 10¢ per dose) and Big Pharma can't make any money off generic cures.

Peak Prosperity's Dr. Chris Martenson breaks down the phony VA "study" and cites scientific evidence to conclude that the VA's review of patients in latter stages of the disease was "garbage." in this exceptional video. You are strongly urged to watch it and make up your own mind.



Getting to recent developments, the Labor Department reported minutes ago that another 4.4 million Americans filed for unemployment benefits in the past week, bringing the five week total to over 26 million.

Meanwhile, the US economy is floundering, as are the economies of almost all developed nations. The global depression, brought to you by the Federal Reserve in conjunction with the US federal government, the fake mainstream media and Big Pharma, is in full bloom and will affect life p in varying degrees - for billions of people for years.

Buy gold and silver if you can. Also consider bitcoin or other cryptocurrencies and getting off the electrical grid as much as possible, returning to a simpler lifestyle and out of the modern-day, neo-feudal rat race.

Finally, this clip from Family Guy offers metaphor for how many Americans (especially seniors who didin't file taxes in 2018 or 2019 -- think: poor people) feel about Treasury Secretary's five-week old promise to have $1200 checks in the hands of Americans "within two weeks."



At the Close, Wednesday, April 22, 2020:
Dow: 23,475.82, +456.94 (+1.99%)
NASDAQ: 8,495.38, +232.15 (+2.81%)
S&P 500: 2,799.31, +62.75 (+2.29%)
NYSE: 10,908.56, +202.12 (+1.89%)

Stocks Rise, Then Fall, End Flat; Dow Up 16X in 31 Years Though Not the Same

Stocks flew at the open, making the highs of the session, then backtracked, recovered and finally flat-lined until 3:00 pm ET, when selling commenced, taking the indices back to break-even for the day.

It was mostly a senseless trade, kicking off a holiday-shortened week which will feature lower volume than usual (if that's possible) and giddiness surrounding the holiday shopping season, which almost always produces an up session on the short Friday after Thanksgiving.

A few friends were commenting on the wisdom of a buy and hold strategy for the long haul as the Dow Jones Industrials crossed the 16,000 threshold this past Friday. One idea was that holding an index fund of Dow stocks from late 1982 to the present would have resulted in a 16X return on your money, or $10,000 invested in the Dow in 1982 - the last time the Dow crossed the 1000 mark and did not fall below it - would be worth $160,000 today.

It's an interesting concept, but, in case somebody wanted to just buy all the individual stocks in the Dow 30 blue chips, it would have probably been a more profitable, albeit time-consuming endeavor. Of the 30 stocks in the Dow today, only 10 of them were part of the index back in late 1982.

Those ten are AT&T, American Express, IBM, duPont, 3M, Proctor & Gamble, GE, United Technologies, Merck and Exxon (merged with Mobil to form ExxonMobil).

In those 31 years, the composition of the Dow changed 13 times, including eight times since 2003. Not to say that the stocks in the Dow are all magnificent winners, but how one gets a 16X return is by taking out under-performers and replacing them with stocks which have a better chance of appreciation, kind of a shell game, though one could have done well just holding any fund indexed to the famous average.

By way of comparison, the S&P 500 rose from about 140 to the current level just above 1800 in the same time period, a gain of just over 13X. Of course, the S&P has even more movement in and out of the index, and weightings are changed periodically. Overall, it gets re-jiggered more often than the Dow.

It's how Wall Street produces outsize profits for investors; they change the game constantly or as conditions warrant. It begs the question of the wisdom of individual issues and fast money trading.

"It is well enough that people of the nation do not understand our banking and monetary system, for if they did, I believe there would be a revolution before tomorrow morning." --Henry Ford

DOW 16,072.54, +7.77 (+0.05%)
NASDAQ 3,994.57, +2.92 (+0.07%)
S&P 1,802.48, -2.28 (-0.13%)
10-Yr Note 100.10 +0.09 (+0.09%)
NASDAQ Volume 1.74 Bil
NYSE Volume 2.99 Bil
Combined NYSE & NASDAQ Advance - Decline: 2701-2954
Combined NYSE & NASDAQ New highs - New lows: 532-96
WTI crude oil: 94.09, -0.75
Gold: 1,241.20, -2.90
Silver: 19.88, +0.02
Corn: 431.25, +2.00

Fun and Games Friday: Markets Erase Steep Losses, End with Gains

What passes for equity markets in America since 2008 are nothing like the vibrant, progressive institutions prevalent through the halcyon days of the 1990s and prior. Today's casinos are run by big banks and their trick algos, destroying any kind of price discovery in their quest for never-ending profits on the backs of weak companies and even sillier analysts.

Take Amazon (AMZN), for instance. On a day after reporting a loss when they were expected to show a gain for the quarter, along with missing on the revenue side and issuing skeptical guidance, the stock erased early losses and ended the day with a tidy gain. So much for fundamental analysis, price-earnings and other metrics which used to be the norm in real, functioning markets.

Today's casino has no correlation trades except those blessed by upturned-nose analysts from top firms who piece together whatever data they can cherry-pick to make their cases. It's really turned into a situation where it's every man, woman and snooty banker for him/herself.

So it was that the Dow erased all of a 140-point loss incurred in the morning (with all but Merck in negative territory) to finish the day with a modest gain. The NASDAQ was even more extreme, whipping down 20 points in the morning only to gain it all back and turn positive shortly before 2:00 pm EDT and post a 0.22% uptick. There was, as is the usual case, no shaking news or market-moving event, other than that one of the biggest thieves on the planet, Steve Cohen and his firm, SAC Capital, have come under the probing eye of the SEC. Cohen will likely settle before he is even charged and the firm will be liquidated, the money going into the coffers of the federal government, which, of course, needs the money since tax revenues are down severely and the budget process is an absolute mess.

Nothing new on Wall Street this Friday. Just more of the rampant theft and manipulation that has become the trademark of our corrupt, greed-infested markets. That and the reliance of Ben Bernanke's Fed putting a floor under the market is about all one can trust these days.

Good grief. If I hear Maria Bartiromo say, "it looks like it wants to go positive," one more time, there may soon be a busted flat screen left out on my front lawn for the trash man. Today's move was a bad joke. Just look at the A-D line.

Enjoy your weekend in the Hamptons, you rich crooked bums, and don't forget to BTFD.

For the rest of you, more silver, gold, tools, machinery and farm land.

Dow 15,558.83, +3.22 (0.02%)
NASDAQ 3,613.16, +7.98 (0.22%)
S&P 500 1,691.65, +1.40 (0.08%)
NYSE Composite 9,620.42, -14.64 (0.15%)
NASDAQ Volume 1,666,886,250
NYSE Volume 2,991,769,500
Combined NYSE & NASDAQ Advance - Decline: 2758-3710
Combined NYSE & NASDAQ New highs - New lows: 245-63
WTI crude oil: 104.68, -0.81
Gold: 1,321.50, -7.30
Silver: 19.80, -0.35

No News, Stocks Lose

In a very choppy trading session, the major indices fell further to the downside on Monday, as investors were largely left without guideposts. There were no meaningful economic reports nor corporate releases upon which to trade, so the overwhelming overhang of a continuing negative feedback loop sent investors bailing again.

Dow 6,547.05, -79.89 (1.21%)
NASDAQ 1,268.64, -25.21 (1.95%)
S&P 500 676.53, -6.85 (1.00%)
NYSE Composite 4,226.31, -58.18 (1.36%)

Stocks opened lower at the open, but quickly rebounded and traded in positive territory for a while, but by 11:00 am, the bears had taken control again. The only encouraging news was merger-related, though the combinations were deemed dilutive to two companies, one a Dow component: Merck (MRK) and Dow Chemical (DOW). In the pharma sector, Merck signed definitive agreements to purchase Schering-Plough for $41.1 billion in stock and cash. Dow Chemical, meanwhile, convened talks with buyout target Rohm & Haas to resolve thorny issues which have resulted in litigation. Merck lost 1.75, to close at 20.99, the largest percentage decliner on the Dow at a loss of 7.78%. Dow Chemical lost 0.79, to close at 6.32, an 11% loss.

Overall, the Dow finished with 14 stocks up and 16 down, but the severity of the losses was far greater than what amounted to skimpy gains.

In the general market, declining issues outnumbered advancers, 4613-1947, The number of stocks making new lows was again very high, at 1244. There were only 6 new highs. Volume was less than it was last week, reflecting some degree of disinterest or outright exhaustion.

NYSE Volume 1,556,423,000
NASDAQ Volume 2,053,304,000

Commodities were split once again, with oil rising $1.55, to $47.07 on word of more desperate OPEC supply cuts, despite heating oil and natural gas both finishing lower. Natural gas finished at a seasonal low of $3.87, a sign that milder weather through the latter part of February and into March has led to lower consumer demand.

Gold dropped $24.70, to $918.00; silver fell 39 cents, to $12.94.

There is continuing evidence of price destruction in the US and beyond, which will no doubt put pressure on many corporate profits this quarter. Looking out 6 weeks at the next earnings season, prospects continue to dim, and that was reflected in Monday's sluggish trade.

Stocks have now fallen in 14 of the last 18 sessions, resulting in a net loss of 1392 points on the Dow. The DJIA is now off 25% for the year.